Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • Apersure (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • News + Resources
    • News
    • Resource Library
  • Menu Menu

Potential Lost Productivity Resulting from the Global Burden of Myopia

Myopia Control 2020–Where are we and where are we heading

Juvenile Myopia Progression, Risk Factors and Interventions

Five Year Clinical Trial on Atropine for the Treatment of Myopia 2

Facing the Myopia Epidemic

Atropine for treatment of childhood myopia in India (I-Atom)

Recent Posts

  • Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023
  • Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals August 16, 2023
  • Eyenovia Announces First Commercial Sale of MydCombi™ August 3, 2023

Pipeline and Technology

  • MydCombi (Mydriasis)
  • Apersure (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top